Know Labs Inc (KNW) Actualités

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Know Labs, Inc. Announces $300K Registered Direct Offering

Know Labs, Inc. (NYSE American: KNW) (the "Company"), a leading developer of non-invasive medical diagnostic technology, today announced the...

Know Labs, Inc. Announces NYSE American Acceptance of Plan to Regain Compliance

Know Labs, Inc. (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that on December 10, 2024, it...

Know Labs Provides Overview of FY2024 10-K Annual Report

The Company Responds to Shareholder Concerns and Reiterates Progress and Future Plans Know Labs, Inc. (NYSE American: KNW), a leading developer...

Know Labs, Inc. Announces Receipt of Audit Opinion with Going Concern Explanation

Know Labs, Inc. (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that, as previously disclosed in...

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 8-K - Current report

Know Labs Announces Expanded Technology Leadership in its Executive Team

Acceleration of Platform Development to Secure Multiple Strategic Partnerships Know Labs, Inc. (NYSE American: KNW), a leading developer of...